Drug Discovery and Development

In April, The New York Times proclaimed that a gen-AI-driven company that hawked compounded GLP-1 drugs was potentially on track to have $1.8 billion in 2026 sales. The paper also reported that the company, MEDVi, had generated $401 million in sales in 2025, saying it had been given access to unspecified company financials. By then,…

Negative biosensors have often been unusable because, as the sensors lose signal when activity is detected, regions of high enzyme activity can look identical to regions with no activity. Researchers at the University of Illinois Chicago have solved this problem with a new cell imaging method that allows scientists to see previously hidden enzyme activities by flipping the optical readout of…

An estimated 69,000 Americans acquired hepatitis C in 2023, roughly double the mid-2010s rate, even though the disease has been curable with an eight- to 12-week course of oral antivirals for more than a decade. AbbVie’s MAVYRET became the first of those antivirals cleared for acute infection in June 2025, with a 96% cure rate in trial. In the EU,…

As evidence mounts that some hormone receptor-positive, HER2-negative breast cancer patients are being overtreated with chemotherapy, researchers are working to identify which patients can safely avoid it, and to expand the treatment options available to those who can. Atossa Therapeutics thinks endoxifen, the active metabolite behind tamoxifen, could be an important addition to that toolkit.  …